Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


USANA not selling

This article was originally published in The Tan Sheet

Executive Summary

Unity Acquisition Corp.'s tender offer of $28 per share of USANA Health Science's stock is "inadequate and not in the best interests of USANA's shareholders," the Salt Lake City-based firm announces July 3. USANA says the special committee of its board of directors "unanimously" determined the firm should reject Unity Acquisition's offer. This is not the first tender offer USANA has received. In May, Gull Holdings offered to acquire USANA's outstanding shares for $26 per share (1"The Tan Sheet" May 26, 2008, In Brief)...

You may also be interested in...

USANA for sale

USANA Health Sciences' board formed a special committee of independent directors to evaluate a tender offer expected from Gull Holdings, Ltd. and others, to acquire all of its outstanding shares at $26 per share, USANA says May 20. Gull Holdings indicated its intent in a May 13 notice to the Securities and Exchange Commission...

'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips

Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts